It was only nine months ago that Idorsia announced a CEO change, tapping Srishti Gupt | Idorsia is gearing up for another CEO ...

Eli Lilly scored $408 million in U.S. sales of eczema treatment Ebglyss in its first full year on the market in 2025. | With ...

With a fresh phase 3 win for Kerendia, Bayer is one step closer to pushing the ascendant drug into a much broader population ...

BioMarin will discontinue dosing and enrollment of its phase 2 trials for Voxzogo—currently approved in achondroplasia, a ...

The White House’s direct-to-consumer (DTC) platform, TrumpRx, is steadily expanding its catalogue, with products from GSK and Amgen the latest to join the collection of drugs offered through the pr | ...

A federal judge in Boston blocked significant parts of the HHS' vaccination agenda and effectively stopped an upcoming ...

Johnson & Johnson is suing a former oncology medical affairs employee, alleging a massive and “malicious” stealing of trade ...

From its 17-year development cycle through to its commercial launch, production has always been in Yeztugo’s DNA. | From its ...

Veeva is paying approximately $100 million to acquire Ostro, according to this week’s announcement, comprising a combination ...

Simtra BioPharma Solutions was issued a warning letter by the FDA after an inspection uncovered a number of problems at the ...

Twelve months ago, drugmakers came roaring into 2025, fueled by a massive year of growth that peaked in the fourth quarter of ...

In this week’s episode of “The Top Line,” we take a deep dive into the fourth-quarter performance of the biopharma industry ...